• About us
• Contact

Advertisement

Organisation › Details

Novo Group (Group)

Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo A/S is not a corporate strategic fund; Novo A/S invests for financial rather than strategic returns. Novo A/S is active in both Europe and North America. The Novo A/S venture investments are managed by a team of four Partners in Copenhagen, one in London and three in San Francisco. With an evergreen structure, Novo A/S annually invests approximately EUR 200 million through Novo Ventures, Novo Seeds, and Novo Growth Equity. In total Novo A/S has more than EUR 15 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S. *

 

	Start	2004-09-13 existent
	Industry	venture capital
	Region	Denmark_oo
	Country	Denmark
	Street	19 Tuborg Havnevej
	City	2900 Hellerup
	Tel	+45-3527-6500
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2021-12-31

Advertisement

More documents for Novo Group (Group)

• [1] Novo Nordisk A/S. (8/10/23). "Press Release: Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and other Serious Metabolic Diseases". Bagsværd & Montreal....
• [2] Bactolife A/S. (8/8/23). "Press Release: Bactolife Raises EUR 30 Million in Series A Financing". Copenhagen....
• [3] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
• [4] EQT AB. (6/21/23). "Press Release: EQT Private Equity to Sell Ellab, Following Transformation into a Leading Validation & Monitoring Provider for the Biotech and Pharmaceutical Industries"....
• [5] AH Diagnostics A/S. (4/3/23). "Press Release: Helle Zacho Becomes the New CEO of the AH Diagnostics Group"....
• [6] Evosep ApS. (1/9/23). "Press Release: Evosep Receives Strategic Investment from Novo Holdings A/S to Accelerate Its Effort on Clinical Proteomics". Odense....
• [7] Novozymes A/S. (12/12/22). "Press Release: Novozymes and Chr. Hansen to Combine and Create a Leading Global Biosolutions Partner [Not for US, CA, et al.]". Copenhagen....
• [8] Novo Nordisk A/S. (11/22/22). "Press Release: Novo Nordisk Invests DKK 5.4 bn Danish Kroner in Expansion of Clinical Manufacturing Facilities in Bagsværd, Denmark". Bagsværd....
• [9] Inversago Pharma Inc.. (10/19/22). "Press Release: Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors". Montréal, QC....
• [10] Inversago Pharma Inc.. (10/17/22). "Press Release: Inversago Pharma Raises $95 Million CAD in Series C Financing". Montréal, QC....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.